Compare Dishman Pharma with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA JUBILANT LIFE SCIENCES DISHMAN PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 25.1 15.2 164.7% View Chart
P/BV x 3.3 1.8 188.2% View Chart
Dividend Yield % 0.7 0.8 79.3%  

Financials

 DISHMAN PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
JUBILANT LIFE SCIENCES
Mar-19
DISHMAN PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs374898 41.7%   
Low Rs129618 20.9%   
Sales per share (Unadj.) Rs197.8572.0 34.6%  
Earnings per share (Unadj.) Rs21.236.2 58.5%  
Cash flow per share (Unadj.) Rs34.759.5 58.3%  
Dividends per share (Unadj.) Rs2.004.50 44.4%  
Dividend yield (eoy) %0.80.6 133.8%  
Book value per share (Unadj.) Rs179.9301.9 59.6%  
Shares outstanding (eoy) m80.69159.28 50.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.3 96.0%   
Avg P/E ratio x11.920.9 56.7%  
P/CF ratio (eoy) x7.212.7 56.9%  
Price / Book Value ratio x1.42.5 55.7%  
Dividend payout %9.412.4 75.9%   
Avg Mkt Cap Rs m20,306120,694 16.8%   
No. of employees `0000.82.4 34.7%   
Total wages/salary Rs m5,35519,260 27.8%   
Avg. sales/employee Rs Th19,252.738,120.6 50.5%   
Avg. wages/employee Rs Th6,459.58,058.4 80.2%   
Avg. net profit/employee Rs Th2,064.12,414.3 85.5%   
INCOME DATA
Net Sales Rs m15,96191,108 17.5%  
Other income Rs m265357 74.3%   
Total revenues Rs m16,22691,466 17.7%   
Gross profit Rs m4,10317,390 23.6%  
Depreciation Rs m1,0913,709 29.4%   
Interest Rs m9442,198 43.0%   
Profit before tax Rs m2,33411,840 19.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m6243,268 19.1%   
Profit after tax Rs m1,7115,770 29.7%  
Gross profit margin %25.719.1 134.7%  
Effective tax rate %26.727.6 96.8%   
Net profit margin %10.76.3 169.3%  
BALANCE SHEET DATA
Current assets Rs m11,01845,848 24.0%   
Current liabilities Rs m9,51720,897 45.5%   
Net working cap to sales %9.427.4 34.3%  
Current ratio x1.22.2 52.8%  
Inventory Days Days11057 194.6%  
Debtors Days Days3551 68.4%  
Net fixed assets Rs m16,30465,498 24.9%   
Share capital Rs m161159 101.3%   
"Free" reserves Rs m12,90747,930 26.9%   
Net worth Rs m14,51648,089 30.2%   
Long term debt Rs m4,18942,429 9.9%   
Total assets Rs m29,805114,685 26.0%  
Interest coverage x3.56.4 54.3%   
Debt to equity ratio x0.30.9 32.7%  
Sales to assets ratio x0.50.8 67.4%   
Return on assets %8.96.9 128.2%  
Return on equity %11.812.0 98.2%  
Return on capital %17.512.4 141.2%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95212,422 39.9%   
Fx outflow Rs m69717,227 4.0%   
Net fx Rs m4,255-4,805 -88.5%   
CASH FLOW
From Operations Rs m2,78611,215 24.8%  
From Investments Rs m-1,529-10,118 15.1%  
From Financial Activity Rs m-9416,574 -14.3%  
Net Cashflow Rs m3167,612 4.2%  

Share Holding

Indian Promoters % 61.4 45.6 134.6%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 3.7 8.7 42.5%  
FIIs % 12.7 21.2 59.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 21.1 104.7%  
Shareholders   46,261 23,815 194.3%  
Pledged promoter(s) holding % 35.8 15.9 225.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY19); Net Profit Up 25.7% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 25.7% YoY). Sales on the other hand came in at Rs 24 bn (up 15.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS